Composition for inhibiting diabetes mellitus and method of manufacturing the same
A composition for inhibiting diabetes mellitus comprising 1 part by weight of soybean oil, 5 to 14 parts by weight of emulsifier, 0.5 to 2 parts by weight of lecithin, 0.3 to 2 parts by weight of PEG, 81 to 91 parts by weight of deionized water and 2.345 to 17.833 parts by weight of cinnamaldehyde. Furthermore, the present invention also provides a method for manufacturing the composition for inhibiting diabetes mellitus, to produce the aforementioned composition for inhibiting diabetes mellitus.
1 . A composition for inhibiting diabetes mellitus comprising 1 part by weight of soybean oil, 5 to 14 parts by weight of polysorbate-based emulsifier, 0.5 to 2 parts by weight of lecithin, 0.3 to 2 parts by weight of polyethylene glycol (PEG), 81 to 91 parts by weight of deionized water, and 2.345 to 17.833 parts by weight of cinnamaldehyde, wherein an average particle size of the composition for inhibiting diabetes mellitus is ranged between 33 nm to 37 nm, and a polydispersity index of the composition for inhibiting diabetes mellitus is ranged between 0.12 to 0.20.
2 . The composition for inhibiting diabetes mellitus of claim 1 , further comprising 0.14734 to 0.8813 parts by weight of cinnamic acid.
3 . The composition for inhibiting diabetes mellitus of claim 1 , further comprising 0.04122 to 0.4334 parts by weight of cinnamyl alcohol.
4 . The composition for inhibiting diabetes mellitus of claim 1 , further comprising 0.02504 to 0.0833 parts by weight of kaempferol.
5 . The composition for inhibiting diabetes mellitus of claim 1 , further comprising 0.0177 to 0.0947 parts by weight of benzoic acid.
6 . The composition for inhibiting diabetes mellitus of claim 1 , further comprising 0.0102 to 0.156 parts by weight of eugenol.
7 . The composition for inhibiting diabetes mellitus of claim 1 , further comprising 0.0037 to 0.0093 parts by weight of quercetin.
8 . The composition for inhibiting diabetes mellitus of claim 1 , further comprising 0.02504 to 0.0833 parts by weight of kaempferol-3-β-D-glucopyranoside.
9 . The composition for inhibiting diabetes mellitus of claim 1 , further comprising 0.0011 to 0.0067 parts by weight of rutin.
10 . The composition for inhibiting diabetes mellitus of claim 1 , further comprising 0.00108 to 0.00521 parts by weight of caffeic acid, 0.00086 to 0.0012 parts by weight of coumarin, 0.00038 to 0.0014 parts by weight of hyperoside and isoquercetin, 0.00080 to 0.001 parts by weight of p-coumaric acid, and 0.00012 to 0.0015 parts by weight of neochlorogenic acid.